Extremely unlikely to break a dollar....best case range .85 to .93 with equivalent possibility of mid .40s again by August.... Sorry, but that's REALLY the 'truth 4 once.'
And just so the thread is clear: First, I was correct in calling you out on the consultants. There were indeed two, not one. Second, while JT is presumably a very nice fellow, neither HE or YOU are the actual source of the information which substantiates factual claims. Facts can only be sourced from publications, CCs, and other such known documentation. Facts are not our opinions OR our recollections of past experience, although they may be included therein. In the future, I will continue to stick to them when making formal assertions and most especially when not just venting for opinion's sake. I humbly suggest you do the same.
SB never allows money to flow to shareholders. He and MR plan to dilute to raise more for the "pipeline train," as was alluded to in the CC when they talked about PN planning. They usually pull their rabbit trick encumbrances in late summer but this year's anyone's guess. If I were a betting man, I'd wager the borrowing will begin around the same time they publish positive study results, which can also be assumed given the canny way they discussed it, again in the CC. Expenses related to Probuphine go to Braeburn, as do the lion's share of any profits due its commercialization. In order to maintain their never ending gravy train, Titan will have to borrow (dilute) in order to finance it, since they've now parlayed away most of Probuphine, as they did with their last successful approval (debatable), called Fanapt. Besides, Probuphine won't produce a dime in time for the PN pitch, so dilution is a given, in my opinion. Perhaps it's not the case but the way it looks is that Titan's business plan has always been failure, a point much debated here through the years. While it's been profitable venture for insiders like SB, MR, their vendors, venture capital cronies and the BOD, Titan's shareholders have lost a massive number of millions of dollars over the past two decades of this company's operation. This is why I'll only swing trade Titan, which I consider OTC trash paper now. It's not, by any stretch of the imagination, or wishful thinking, a viable term investment consideration, in my opinion. There is money to be made but by trading swings. We're in the midst of a promising cycle in that regard. Watch the SP drift higher, then crash......... Time it if you can but don't be surprised if you're left without a chair when the music stops. The gang has an inside trading track, making retail transactions, tenuous at the least. Best not to wait too long to act on the swings and stay out of the tight margins. You'll lose every time.
Not important we put too fine a point on that anyway Jon, seeing as how Titan's more or less done the deed, so to speak. My concern now is for the game they continue to play. So, now they've alluded, in yet another CC, to putting the PN train on a 2016 start-up schedule. That means dilution no matter how it's framed, as any Probuphine revenue (potential) won't be garnered by time near the referenced PN ramp up. MR said 2016, so the beat goes on, more or less (most likely less) to the monetary detriment of investors. True to form, it looks like Titan will remain an OTC near pink indefinitely.
Cite it or don't bother to dispute it Jon (Nowak488). You know the rules. Call me out. That's OK. Do so with FACTS, otherwise, you're wrong. "Pretty sure" isn't material and you know it. FACT: SB continually refers to consultants...plural, in CCs Q3 and Q4 2011, SB and others, throughout conference calls Q1, 2012, Q2 2012 and Q4 2012. I have the recordings. As for the amount that was paid, you should recheck your figures, as that $750K is wholly inaccurate. Plus, they weren't paid in a single payment either, according to the filings. Not just that, but the POINT I was ACTUALLY making is that the consultants were literally PAID FOR DOING ABSOLUTELY NOTHING AT ALL, since they didn't find us a partner did they? Meantime what is Braeburn really? Go ahead, show me a REASON why you believe Braeburn to be such good thing in this scenario....I'll wait....two years post the CRL now and counting that we've been waiting. By the way: Let's hope they don't get into any bigger hurry, otherwise the BIG CRUNCH is more likely to have happened than Titan's NDA re-filing........
I doubt they ever were. Don't you remember the so-called 2 consulting companies SB claimed to have hired to find Titan a partner? These outfits were never named and seemed to just disappear, but were paid, according the filings, in what amounts to little more than an innocuous line item. Accordingly, Titan's consultants never found them a partner but later, Braeburn just materialized to save the day, so nobody bothered to press the issue. We checked their (Breburn's) credentials long ago. They're little more than an umbrella outfit for a hedge fund, with no sales team, virtually no credentials for selling dog food, much less pharmaceuticals. I've long maintained we were deceived as shareholders. So, we let things play out and the next shoe that drops is we find the study has failed, or they'll drag their feet another two years to buy time (and millions) to pump some other pie in the sky pipeline product. If that happens, they'll have more than "not holding shareholder meetings" in the way of litigation defense issues. I guarantee it.
Positive earnings Jon? Seriously? Where will that come from exactly? When last I looked they were more than likely to want to dilute yet again, in order to keep clowns in grease paint...aka the Titan pipeline. Did they acquire a significant revenue stream from another source and forget to mention it to shareholders? If so, that would be both refreshing and SOoooooo..... SB. Not saying it couldn't/wouldn't happen but frankly, if the positive revenue is some inconsequential amount or once again, some evaporated funds imagined through creative accounting, it doesn't count.
I always enjoy your fact-filled pro-Titan posts barme93. They aptly inspire thought. Frankly, I remain VERY suspicious of Braeburn and their likely actions. I also give Probuphine viability a cautious nod, while remaining not wholly convinced of its imminent approval. A week or month's dosing is truly not the PB asset. As you've written, the asset is abuse deterrence. The problem for me has always been about their REMS, which I cannot see them pragmatically overcoming, shot in proverbial foot as it were, by PB having been relegated in the FDA's CRL to a second line therapy by default, regardless any greater substance contained in the next forthcoming NDA submission. Titan was asked to address specific concerns in their followup studies. It will be interesting to learn those results but their silence is deafening, and is also greatly uncharacteristic by comparison to their previous attempts. While I find Titan's efforts far from hopeless, results will prove, once and for all, this question. Meantime, the object for traders and investors is to profit. IMO holding any shares with a basis greater than .43 is a genuine threat to that goal. If Probuphine fails, even .03 will be a high benchmark.
Even a broken clock gets it right twice a day, but JN hasn't had a good record in predicting anything about TTNP so far, as you very well know. Every time he publishes one of his pump pieces it signals volatility ahead, and almost always leads the SP lower than it was before his trumpeting how undervalued Titan is. JN also has a record of asking some of the most obvious and suspiciously leading questions at CCs. Through the years, I've grown suspect of Zacks (JN's employer) and their cozy relationship with the companies they cover, including Titan. So, when a couple of more credible financial analysts share JN's opinion, his predictions will be more believable to me.
If you think this will go to 3 bucks, please buy, buy, buy. I have about 60K shares waiting for you to buy at the ask of .71.
Been here every day for six years...not going anywhere. How old is your zkhanna ID Dave? Again, you cannot short a pink BB stock idiot .....nice try but keep posting.....I love to make fools out of shills and newbie liars....
Hey dummy, it's not possible to short Titan unles you're a MM...as is the case with most pink and BB OTCs. And the only way this will ever see 2.00 again is through a reverse split. But keep pumping....new money means gaps for traders...lol
Not for nothing baxter but Braeburn has never seemed an eager partner to me. And they sure don't seem all that invested in Probuphine's success one way or another, evidenced by their record of silence on the public stage. To me, Braeburn never actually behaved all that enthused, which should make an intelligent person wonder just what game they might be playing. Now, all this time later, it would seem we've aligned with either a passive partner or possibly worse still, a shill. I've said all along how the little things add up, beginning with the fact that even Braeburn's website was constructed from a template freely available (cheaply) on the web (see: monstertemplates). I'm not sure if you can still do it or not but if you click the "view source" on their webpages and scan their code (which any web developer worth his salt would have locked), you'll also find some interesting reference links. I know I have a suspicious nature but I've never trusted this Braeburn outfit was on the up and up, if for no other reason than the fact that it took Titan years to even find them, after apparently no one in the world would have anything to do with them or their Probuphine. Do you remember the (2) phantom consultants that SB used to brag about during the CCs and Titan paid to find them a partnership deal? If you read their filings you'll find a handsome citation amount for their payment BUT also remember, they ever named to shareholders. And as far as I can tell, they were not involved at all in the Braeburn association. So much suspicious junk has gone on with Titan these past six years, I've grown increasingly skeptical of their legitimacy, which is why I trade now.
That wouldn't be surprising to me if proven. Plus, it would give Titan's shareholders one BIG stake in RB, since there is a published study, conducted and abandoned by RB in 2010 that is PRECISELY the same thing as Probuphine. That fact would go a long way in litigation, should RB's hand be caught in the cookie jar. Meantime, RB's shills would have been the two most identifiable cretins on the FDA's panel, in my opinion.
I don't see how, since they've been operating at a loss for a while. Remember, there are other requirements too, besides the 3 standards I list above, most or all of which disqualify them too.